Journal: Cancers

Article Title: Anti-MAPK Targeted Therapy for Ameloblastoma: Case Report with a Systematic Review

doi: 10.3390/cancers16122174

Figure Lengend Snippet: Demographics (M male, F female, NS non-specified, IHC Immunohistochemistry, NGS next-generation sequencing, PCR polymerase chain reaction, BID twice a day, QD once a day, CR complete response, NCR near-complete response, PR partial response, SD stable disease, N no, TTT treatment).

Article Snippet: The histopathologic examination revealed ameloblastoma ( A), with positive immunohistostaining for BRAF V600E (clone VE1, Ventana Medical Systems, B).

Techniques: Immunohistochemistry, Next-Generation Sequencing, Polymerase Chain Reaction

Journal: PLoS ONE

Article Title: Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay

doi: 10.1371/journal.pone.0221123

Figure Lengend Snippet: Comparison of BRAF and NRAS results by allele specific amplification, Sanger sequencing, IHC and Idylla testing.

Article Snippet: Slides were stained with anti-BRAF V600E mutant-specific antibody (clone VE1, dilution 1:200, pH9, Eurobio) [ ] .

Techniques: Comparison, Amplification, Sequencing, Mutagenesis

Journal: PLoS ONE

Article Title: Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay

doi: 10.1371/journal.pone.0221123

Figure Lengend Snippet: A. Control of samples found positive for BRAF mutation by ASA/Sequencing but negative by IHC. B. Control of samples found negative for BRAF mutation by ASA/sequencing and positive by IHC (wrong chromogen used). C. Control of samples found positive for NRAS mutation by sequencing but negative by Idylla. Yellow dots correspond to wild type DNA copies ( BRAF , panels A and B; NRAS , panel C). Green dots correspond to mutated DNA copies ( BRAF V600E, panels A and B; NRAS Q61R, panel C). Grey dots correspond to empty wells.

Article Snippet: Slides were stained with anti-BRAF V600E mutant-specific antibody (clone VE1, dilution 1:200, pH9, Eurobio) [ ] .

Techniques: Control, Mutagenesis, Sequencing

Journal: PLoS ONE

Article Title: Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay

doi: 10.1371/journal.pone.0221123

Figure Lengend Snippet: Discordant genotyping results.

Article Snippet: Slides were stained with anti-BRAF V600E mutant-specific antibody (clone VE1, dilution 1:200, pH9, Eurobio) [ ] .

Techniques: Digital PCR

Journal: Brain Pathology

Article Title: New clinicopathological associations and histoprognostic markers in ILAE types of hippocampal sclerosis

doi: 10.1111/bpa.12596

Figure Lengend Snippet: CD34+ cells are associated with rarer patterns of hippocampal sclerosis. A–D, I–J. A CD34+ nodular case. CD34 immunopositive/CD34+ stellate cells formed a nodule (solid arrowheads in (A‐B). Nestin immunolabeling showed a frequent extravascular stellate pattern in the area of the CD34+ nodule (solid arrowhead in C) whereas Vimentin immunolabeling showed no extravascular immunolabeling (D). E–H, K–L. A CD34+ scarce case. E. An isolated CD34+ extravascular stellate cell is observed (open arrowheads in E, F). Nestin immunolabeling showed a scant stellate extravascular pattern in the area of the CD34+ stellate cell (open arrowhead in G) whereas Vimentin immunolabeling showed no extravascular immunolabeling (H). Double immunolabelings showed the co‐expression in stellate cells of Nestin (brown) and CD34 (red) (I), and SOX2 (pink) and CD34 (brown) (J) in a CD34+ nodular case. Double immunolabelings showed the co‐expression in stellate cells of Nestin (brown) and CD34 (red) (K, higher magnification in insert), and of SOX2 (pink) and CD34 (brown) (L) in a CD34+ scarce case. M–P. Distribution of CD34 immunolabeling (CD34 negative in black, CD34+ scarce in orange and CD34+ nodular in green) for type 1 (M), type 2 (N), type 3 (O), the pattern noHS (P). Q–S. A CD34+ nodular case with BRAF V600E immunopositive neurons. Q. A moderate immunolabeling of scarce cells by P53 (solid arrowheads). The BRAF V600E immunolabeling is positive in neurons (solid arrowheads in r,s). T. A CD34+ scarce case with BRAF V600E+ neurons (open arrowhead). Scale bars: (A,E) 400 μm; (B–D,F–H) 100 μm; (I–L,T) 50μm; (Q,R) 200μm; (S) 20μm.

Article Snippet: Primary antibodies were as follows: BRAF V600E (mouse monoclonal VE1, 1:100, Abcys Eurobio), CD31 (monoclonal mouse JC70A, 1:30, Dako) CD34 (monoclonal mouse QBEnd10, 1:50, Dako), ELAVL2 (rabbit polyclonal, 1:500, Proteintech), GFAP (monoclonal mouse 6F2, 1:500, Dako), Internexin alpha/INA (monoclonal mouse 2E3, 1:100, Quartett Biochemicals), Nestin (monoclonal mouse 10C2, 1:2000, Sigma‐Aldrich), NeuN (Monoclonal mouse MAB377, 1:100; Merck Millipore), OLIG2 (rabbit monoclonal EP112, 1:200, Epitomics), P53 (monoclonal mouse, DO‐7, 1:100 Dako), SOX2 (rabbit monoclonal SP76, 1:300, Sigma‐Aldrich), Vimentin (monoclonal mouse V9, 1:50 Dako).

Techniques: Immunolabeling, Isolation, Expressing

Journal: Brain Pathology

Article Title: New clinicopathological associations and histoprognostic markers in ILAE types of hippocampal sclerosis

doi: 10.1111/bpa.12596

Figure Lengend Snippet: Classification of CD34+ hippocampal sclerosis according to BRAF V600E and INA status. A,C,E,G–I. A case of “BRAF V600E+ HS” with BRAF V600E positive neurons. B,D,F,J–L. A case of hippocampal MVNT. A,B. CD34 immunolabeling showed a nodular pattern of CD34 positive stellate cells (solid arrowheads). C,D. NeuN immunolabeling showed a neuronal loss that is predominant in CA4 (solid arrowheads) corresponding to HS ILAE type 3. E. Absence of INA positive abnormal neurons. F. Presence of numerous abnormal INA+ neurons (solid arrowheads). G–I. Absence of abnormal neurons according to NeuN, ELAVL2 and INA immunolabelings in the white matter of CA2 (open arrowheads) in a BRAF V600E+ HS. J–L. Presence of Neun Negative, ELAVL2 positive, INA positive abnormal neurons (solid arrowheads) in the white matter of CA2 in a MVNT. Scale bars: (A–F) 2.5 mm; (G–L) 200 μm. Abbreviations: INA = internexin alpha; MVNT = multinodular and vacuolating neuronal tumor.

Article Snippet: Primary antibodies were as follows: BRAF V600E (mouse monoclonal VE1, 1:100, Abcys Eurobio), CD31 (monoclonal mouse JC70A, 1:30, Dako) CD34 (monoclonal mouse QBEnd10, 1:50, Dako), ELAVL2 (rabbit polyclonal, 1:500, Proteintech), GFAP (monoclonal mouse 6F2, 1:500, Dako), Internexin alpha/INA (monoclonal mouse 2E3, 1:100, Quartett Biochemicals), Nestin (monoclonal mouse 10C2, 1:2000, Sigma‐Aldrich), NeuN (Monoclonal mouse MAB377, 1:100; Merck Millipore), OLIG2 (rabbit monoclonal EP112, 1:200, Epitomics), P53 (monoclonal mouse, DO‐7, 1:100 Dako), SOX2 (rabbit monoclonal SP76, 1:300, Sigma‐Aldrich), Vimentin (monoclonal mouse V9, 1:50 Dako).

Techniques: Immunolabeling

Journal: Brain Pathology

Article Title: New clinicopathological associations and histoprognostic markers in ILAE types of hippocampal sclerosis

doi: 10.1111/bpa.12596

Figure Lengend Snippet: Radiological features of BRAF V600E+ hippocampal sclerosis and hippocampal MVNT. A‐B. BRAF V600E+ hippocampal sclerosis. Coronal T2 sequence showing discrete atrophy, loss of digitation and T2 hyperintensity of the right hippocampus (vertical arrows). C–E. Hippocampal MVNT. Coronal T2 (C), FLAIR (D) and T1 (E) sequences show discrete atrophy of left internal temporal structures (vertical arrows), associated with extensive T2 and FLAIR hyperintensities involving the hippocampus, parahippocampal gyrus, fusiform gyrus and part of the inferior temporal gyrus (oblique arrows). A pseudocyst (arrowheads) is visible within the fusiform gyrus, hyperintense on T2 and hypointense on T1 and FLAIR images.

Article Snippet: Primary antibodies were as follows: BRAF V600E (mouse monoclonal VE1, 1:100, Abcys Eurobio), CD31 (monoclonal mouse JC70A, 1:30, Dako) CD34 (monoclonal mouse QBEnd10, 1:50, Dako), ELAVL2 (rabbit polyclonal, 1:500, Proteintech), GFAP (monoclonal mouse 6F2, 1:500, Dako), Internexin alpha/INA (monoclonal mouse 2E3, 1:100, Quartett Biochemicals), Nestin (monoclonal mouse 10C2, 1:2000, Sigma‐Aldrich), NeuN (Monoclonal mouse MAB377, 1:100; Merck Millipore), OLIG2 (rabbit monoclonal EP112, 1:200, Epitomics), P53 (monoclonal mouse, DO‐7, 1:100 Dako), SOX2 (rabbit monoclonal SP76, 1:300, Sigma‐Aldrich), Vimentin (monoclonal mouse V9, 1:50 Dako).

Techniques: Sequencing